Human medicines European public assessment report (EPAR): Lamivudine Teva, lamivudine, Date of authorisation: 23/10/2009, Revision: 14, Status: Authorised
Opinion/decision on a Paediatric investigation plan (PIP): Menveo, Meningococcal group A oligosaccharide conjugated to Corynebacterium diphteriae CRM197 protein (MenA-CRM) Meningococcal group C oligosaccharide conjugated to Corynebacterium diphteriae CRM197 protein (MenC-CRM) Meningococcal group W-135 oligosaccharide conjugated to Corynebacterium diphteriae CRM197 protein (MenW-CRM) Meningococcal group Y oligosaccharide conjugated to Corynebacterium diphteriae CRM197 protein (MenY-CRM), decision type: W: decision granting a waiver in all age groups for all conditions or indications, therape
It is with great pleasure that we present to you EFIM's Annual Report for the year 2023.
This comprehensive report summarizes multiple achievements, advancements, and milestones we have reached over the past year.
Enjoy reading the full report, which reflects our accomplishments, and remain actively engaged in EFIM activities.
We would like to extend our deepest gratituted to all the EFIM Members involved closely in EFIM activities who have dedicated their time and expertise to the content of this annual report.
EMEA-003370-PIP01-22
EMEA-003364-PIP02-22
EMEA-003339-PIP02-23
EMEA-003302-PIP01-22
EMEA-003279-PIP01-22
EMEA-003251-PIP01-22
EMEA-003208-PIP02-22